Point-of-Care Diagnostics: Technologies and Global Markets

Report Highlights

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Report Includes

• 98 data tables and 46 additional tables
• An overview of the global markets and technologies for point-of-care (POC) diagnostics
• Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029
• Estimates of the market size and revenue forecasts for the PoC diagnostics market, with market share analysis by test type, product type, end user, and region
• Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
• Coverage of government regulations and policies, R&D initiatives, exploration activities, and government programs
• Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG scores, and consumer attitudes
• Competitive intelligence, including companies’ market shares, recent M&A activity and venture funding
• Profiles of the leading companies, including Abbott, BD, Danaher Corp., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche Ltd.

Report Scope

The point-of-care diagnostics market is extensive and constantly evolving with new technologies and methodologies. This report explores the current and future market potential, competitive environment, regulatory scenario, and market trends, including projections through 2029 and an analysis of key players.

This report covers the entire industry, including hardware (devices, equipment, consumables), software, and analytics. The market is analyzed by test type, including alcohol and drug abuse, blood gas electrolyte and metabolite (BGEM), cardiac markers, cholesterol, glucose monitoring, hemoglobin/hemostasis, infectious disease, pregnancy and fertility, tumor markers, and urine chemistry, and it includes comprehensive regional analyses.

The report highlights ongoing R&D efforts focused on improving accuracy accessibility and incorporating innovative diagnostic procedures. It provides insights into market drivers, challenges, opportunities, industry status, developments, trends, and strategies like mergers, acquisitions, and collaborations. It is a valuable resource for market players, potential entrants, government agencies, and other stakeholders, especially those interested in geographic expansion.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.